Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0952 crossover study in mild-to-moderate Alzheimer's disease
2006-003924-13Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MK-0952 in Alzheimer's disease (AD) (2 arms), sponsored by Merck & Co. Primary endpoints: Mean change from baseline to week 4 in 0- to 24-hour difference in WLL-SR Summary Score and 2- to 24-hour correct response percentage difference in WLL-DR. Started Dec 2008; status: terminated.
02
Drugs
MK-0952
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2006-003924-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003924-13.